Earnings Call · Q1 FY2024·2024-05-14

Q1 24EPS -58.33%·Rev n/aQ4 23EPS -90.91%·Rev n/aQ3 23EPS +100.00%*·Rev n/aQ2 23EPS -11.76%·Rev n/a⚠ consensus missing

Starling Oncology, Inc. TOI

Mihir Shah — Chief Financial Officer

Daniel Virnich — Chief Executive Officer

+3.5%1d on move date+3.1% vs SPY3d−22.5%5d−29.8%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TOI calls or request research access.

More TOI calls Browse calls Request research access